E-News Newsletter - June 2018

 

 

 




Alliance NCTN at 2018 ASCO

The 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) convened in Chicago June 1-5 with Alliance Group Chair Monica M. Bertagnolli, MD, at the helm as ASCO President for the 2018-19 term. The ASCO meeting brought together more than 30,000 oncology professionals from around the world. This year's meeting theme was "Delivering Discoveries: Expanding the Reach of Precision Medicine." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, were highlighted.  

Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance scientists presented more than 20 studies, sharing the latest findings on breast cancer, brain cancer, hematologic cancers, and gastric cancer, along with cancer control research. The Alliance was well-represented with dozens of researchers participating on panels, discussing new research and giving poster presentations.
 
Take a look back at the Twitter conversation at #ASCO18 and @ALLIANCE_org
 
Here's a snapshot of the studies.
 
Breast Cancer
Increasing adherence to adjuvant hormone therapy among breast cancer patients: A smart phone app-based pilot study
Presenter: Jessica L. Krok-Schoen
Abstract No: e12523 | Citation: J Clin Oncol 36, 2018 (suppl; abstr e12523)
Publication-only
NCT02400060   

Alliance A011401
The Breast Cancer Weight Loss (BWEL) Trial: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401)
Presenter: Jennifer A. Ligibel
Poster Session (Board #89a)
Saturday, June 2, 8 am to 11:30 am - Hall A
Abstract No: TPS598 | Citation: J Clin Oncol 36, 2018 (suppl; abstr TPS598)   
NCT02750826   

ACOSOG Z1071
Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071  
Study Chair: Judy C. Boughey  
Saturday June 2, 8 am to 11:30 am - Hall A (Poster Session - Board #5)
Saturday June 2, 3 pm to 4:15 pm - Hall D1 (Poster Discussion Session)
Abstract No: 513 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 513)
NCT00881361
 
NCCTG N9831
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in NCCTG N9831 (Alliance) and NeoALTTO trials
Presenter: S. Chumsri
Poster Session (Board #69)
Saturday, June 2, 8 am to 11:30 am - Hall A
Abstract No: 577 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 577)
NCT00898898
NCT00553358

Gastrointestinal Cancer
Alliance A031203
ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)
Presenter: D. Feldman
Abstract No: e18690 | Citation: J Clin Oncol 36, 2018 (suppl; abstr e18690)
Publication-only
NCT01835158   

CALGB 80405
Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC)
Presenter: Federico Innocenti
Poster Session (Board #63)
Sunday, June 3, 8 am to 11:30 am - Hall A
Abstract No: 3570 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 3570)
 
CALGB 80702
Effect of age and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: the IDEA collaboration
Presenter: Anthony F. Shields
Poster Session (Board #92)
Sunday, June 3, 8 am to 11:30 am - Hall A
Abstract No: 3599 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 3599)
NCT01150045   

CALGB 80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8)
Presenter: Ghassan K. Abou-Alfa
Abstract No: e16107 | Citation: J Clin Oncol 36, 2018 (suppl; abstr e16107)
Publication-only
NCT01015833   

NCCTG N0147
Genome-wide association with survival in stage II-III colon cancer (CC) clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology)
Presenter: Kathryn Penney
Poster Session (Board #75)
Sunday, June 3, 8 am to 11:30 am - Hall A
Abstract No: 3582 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 3582)
 
NCCTG N0147
Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant therapy trial: NCCTG N0147 (Alliance)
Presenter: Frank A. Sinicrope
Poster Session (Board #76)
Sunday, June 3, 8 am to 11:30 am - Hall A
Abstract No: 3583 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 3583)
 
NCCTG N0147
CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance)
Presenter: Harry H. Yoon
Poster Session (Board #91) Sunday, June 3, 8 am to 11:30 am - Hall A
Abstract No: 3598 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 3598)
 
NCCTG N1048
Variability of pelvic MRI performance in a prospective multicenter rectal cancer trial (Alliance)
Presenter: Marc J. Gollub
Abstract No: e18783 | Citation: J Clin Oncol 36, 2018 (suppl; abstr e18783)
Publication-only

ACOSOG Z5041
A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG/Alliance Z5041 trial
Presenter: Alice C Wei
Poster Session (Board #301)
Sunday, June 3, 8 am to 11:30 am - Hall A
Abstract No: 4112 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 4112)   
NCT00733746
 
CALGB 80803
Survival outcomes from CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer
Presenter: Karyn A. Goodman
Sunday, June 3, 8 am to 11:30 am - Hall A | Poster Session
Sunday June 3, 4:45 pm to 6 pm - Hall D2 | Poster Discussion Session (Board #201)
Abstract No: 4012 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 4012)   
NCT01333033   

Genitourinary Cancer
Alliance A031203
Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203)
Presenter: RC Chen
Poster Session (Board #382)
Saturday, June 2, 8 am to 11:30 am - Hall A
Abstract No: 4556 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 4556)
NCT01835158   

Head and Neck Cancer  
Alliance A091101
A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101
Presenterr: Michael J. Jelinek
Session: Head and Neck Cancer | Poster Session (Board #19)
Saturday June 2, 1:15 pm to 4:45 pm - Hall A
Abstract No: 6031 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 6031)   
NCT01711541
 
Melanoma/Skin Cancers
Alliance A091605
A randomized phase II study of anti-pd1 antibody [mk-3475 (pembrolizumab)] alone versus anti-pd1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (ALLIANCE A091605)
Presenter: Jason Luke
Poster Session (Board #424a)
Monday June 4, 1:15 pm to 4:45 pm - Hall A
Abstract No: TPS9599 | Citation: J Clin Oncol 36, 2018 (suppl; abstr TPS9599
NCT03304639   

Multiple Myeloma
CALGB 100104, E4A03, MM-002, MM-009
Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance)
Presenter: Sikander Ailawadhi
Poster Session (Board #59)
Monday, June 4, 8 am to 11:30 am - Hall A
Abstract No: 8050 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 8050)

Sarcoma
Alliance A091105
Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105)
Presenter: Mrinal M. Gounder
Oral Abstract Session
Monday, June 4, 8 am to 11 am | S100a
Abstract No: 11500 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 11500)
NCT02066181

Cancer Prevention, Hereditary Genetics, and Epidemiology
CALGB 70806
Influence of vitamin D (Vit D) on mammographic density (MD) and insulin like growth factor 1 (IGF1): results of CALGB (Alliance) 70806
Presenter: Marie Wood
Poster Session (Board #120)
Saturday, June 2, 1:15 pm to 4:45 pm - Hall A
Abstract No: 1549 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 1549)   
NCT01224678   

Patient and Survivor Care
Alliance A151715, CALGB 8541, CALGB 40101, CALGB 49907, CALGB 9344, CALGB 9741, NCCTG N89-30-52, NCCTG N9831
Is there a role for older-patient-specific trials? a pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715)
Presenter: Dyda Dao
Poster Session (Board #22)
Monday, June 4, 1:15 pm to 4:45 pm - Hall A
Abstract No: 10034 | Citation: J Clin Oncol 36, 2018 (suppl; abstr 10034)
 

ALLIANCE FOUNDATION TRIALS (AFT)

Genitourinary Cancer
AFT-19
A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19)
Presenter: Rahul Aggarwal
Poster Session (Board #315a)
Saturday, June 2, 1:15 pm to 4:45 pm - Hall A
Abstract No: TPS5090 | Citation: J Clin Oncol 36, 2018 (suppl; abstr TPS5090)
NCT03009981
 
Health Services Research, Clinical Informatics, and Quality of Care  
AFT-30
Frequency of post-treatment surveillance and survival in localized prostate cancer: a national study
Presenter: Ronald Chen
Oral Abstract Session
Friday, June 1, 2:45 pm to 5:45 pm - S404
Abstract No: 6503 Citation: J Clin Oncol 36, 2018 (suppl; abstr 6503)

 

 

For other articles in this issue of the Alliance E-News newsletter, see below.